These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8187800)

  • 21. Effect of rufloxacin upon non-specific immune defences: in-vitro, ex-vivo and in-vivo results.
    Cuffini AM; Tullio V; Allocco A; Paizis G; De Leo C; Carlone NA
    J Antimicrob Chemother; 1994 Oct; 34(4):545-53. PubMed ID: 7868406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The new 4-quinolones DU-6859a and DV-7751a show enhanced activity against Streptococcus pneumoniae.
    Morrissey I; Smith JT
    Drugs; 1995; 49 Suppl 2():228-9. PubMed ID: 8549312
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.
    Molinari G; Schito GC
    Drugs; 1995; 49 Suppl 2():222-5. PubMed ID: 8549310
    [No Abstract]   [Full Text] [Related]  

  • 24. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
    Aihara M; Oguri T; Kanno H; Kubo S; Honda M; Satoh K; Daimon Y; Yamanaka K; Sugawara K; Furuta T
    Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)).
    Sewell DL; Barry AL; Allen SD; Fuchs PC; Murray PR; Tenover FC
    J Antimicrob Chemother; 1996 Jan; 37(1):139-43. PubMed ID: 8647755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative in vitro activity of BAY Y 3118 against selected species.
    Verbist L; Verhaegen J
    Drugs; 1995; 49 Suppl 2():264-5. PubMed ID: 8549326
    [No Abstract]   [Full Text] [Related]  

  • 27. ESGAB breakpoint determination: temafloxacin.
    Phillips I; Acar J; Baquero F; Bergan T; Forsgren A; Wiedemann B
    Eur J Clin Microbiol Infect Dis; 1991 Nov; 10(11):991-2. PubMed ID: 1665417
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones.
    Lister PD
    J Antimicrob Chemother; 2003 Jan; 51(1):199-202. PubMed ID: 12493819
    [No Abstract]   [Full Text] [Related]  

  • 29. The antimicrobial activity of sparfloxacin, a new quinolone.
    Paradelis AG; Delidou K; Grigoriadou A; Salpigides G; Pangalis A
    Drugs; 1995; 49 Suppl 2():238-9. PubMed ID: 8549316
    [No Abstract]   [Full Text] [Related]  

  • 30. Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae.
    Dalhoff A
    Drugs; 1995; 49 Suppl 2():194-6. PubMed ID: 8549301
    [No Abstract]   [Full Text] [Related]  

  • 31. [Lomefloxacin hydrochloride (Maxaquin), a long-acting fluoroquinolone (information for specialists)].
    Kuznetsovoĭ SM
    Antibiot Khimioter; 1998; 43(2):40-1. PubMed ID: 9551172
    [No Abstract]   [Full Text] [Related]  

  • 32. [The difluoroquinolone lomefloxacin--an broad spectrum antimicrobial drug].
    Padeĭskaia EN; Iakovlev VP
    Antibiot Khimioter; 1998; 43(2):30-9. PubMed ID: 9551171
    [No Abstract]   [Full Text] [Related]  

  • 33. The in-vitro activity of a new highly active quinolone, DU-6859a.
    Jolley A; Andrews JM; Brenwald N; Wise R
    J Antimicrob Chemother; 1993 Nov; 32(5):757-63. PubMed ID: 8125840
    [No Abstract]   [Full Text] [Related]  

  • 34. In-vitro activity of a new quinolone, clinafloxacin, against clinical isolates of Corynebacterium species.
    Yagüe G; Herrera EA; Segovia M
    J Antimicrob Chemother; 1996 Oct; 38(4):740-2. PubMed ID: 8937971
    [No Abstract]   [Full Text] [Related]  

  • 35. In-vitro antimicrobial activity of the new fluoroquinolone, grepafloxacin, against pathogenic Nocardia spp.
    Yazawa K; Mikami Y
    J Antimicrob Chemother; 1995 Apr; 35(4):541-4. PubMed ID: 7628988
    [No Abstract]   [Full Text] [Related]  

  • 36. Bactericidal activity, morphological alterations, and synergistic interactions of rufloxacin, a new fluoroquinolone, alone and in combination with its N-desmethylate D derivative (MF 922).
    Marchese A; Debbia EA; Pesce A; Schito GC
    Chemotherapy; 1996; 42(2):90-9. PubMed ID: 8697894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two new fluoroquinolones.
    Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502
    [No Abstract]   [Full Text] [Related]  

  • 39. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study.
    Marco F; Jones RN; Hoban DJ; Pignatari AC; Yamane N; Frei R
    J Antimicrob Chemother; 1994 Mar; 33(3):647-54. PubMed ID: 8040130
    [No Abstract]   [Full Text] [Related]  

  • 40. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones.
    Prats G; Roig C; Miró E; Navarro F; Mirelis B
    Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):328-34. PubMed ID: 12072950
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.